Friday, April 29, 2011 Royal Wedding draws big Internet audience The royal wedding is shaping up as the most-watched live video event in Internet history, according to Akamai Technologies Inc. of Cambridge. Bose makes stock donation to MIT Amar Bose, founder of a Framingham company that bears his name, has given the majority of the stock of Bose Corp. to his alma mater, the Massachusetts Institute of Technology, MIT said today in a statement on its website. Crew Media acquires Eons Crew Media said that it has acquired Eons.com, a baby boomer-focused online social networking site founded by Jeff Taylor of Monster.com fame. Jones will head Harvard innovation lab Gordon S. Jones has been named the director of the Harvard innovation lab, an initiative set to launch later this year that aims to foster team-based and entrepreneurial activities, Harvard University said today. Smoothie King is coming to the Hub Smoothie King, a chain whose specialties include nutritional, fruit-based smoothies, said it has scheduled a grand opening for its new "lifestyle center" at 314 Newbury St. in Boston tomorrow. Watts Water completes acquisition of Danfoss Socla Watts Water Technologies Inc. said that it has completed its previously announced acquisition of Danfoss Socla S.A.S. for a total purchase price of approximately $175.7 million, subject to some conditions. Upromise launches smartphone apps Upromise has announced that smartphone apps are now available for members who have signed up for its college savings program. Comcast expands On Demand TV series options Comcast Corp., which provides cable TV service to many households in Greater Boston, said that it is adding TV series from ABC and FOX to its "On Demand" service, a move that nearly doubles the amount of hit TV series now available from the major broadcast networks. Thursday, April 28, 2011 Panel to FDA: Give OK to Vertex hepatitis C drug A medical advisory committee today unanimously recommended that the US Food and Drug Administration approve a hepatitis C drug developed by Cambridge-based Vertex Pharmaceuticals Inc. |
No comments:
Post a Comment